CJS Securities cut shares of Haemonetics Corp. (NYSE:HAE) from a market outperform rating to a market perform rating in a report published on Tuesday morning. CJS Securities currently has $35.00 price target on the stock.
Several other analysts have also commented on the company. Sidoti lowered Haemonetics Corp. from a buy rating to a neutral rating and set a $39.00 price target on the stock. in a research note on Monday, August 15th. Zacks Investment Research lowered Haemonetics Corp. from a hold rating to a sell rating in a research note on Wednesday, August 3rd. Barrington Research lowered Haemonetics Corp. from an outperform rating to a market perform rating in a research note on Wednesday, August 3rd. Jefferies Group boosted their price target on Haemonetics Corp. from $32.00 to $40.00 and gave the company a buy rating in a research note on Tuesday, August 2nd. Finally, Benchmark Co. boosted their price target on Haemonetics Corp. from $28.00 to $32.00 and gave the company a hold rating in a research note on Tuesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. Haemonetics Corp. presently has an average rating of Hold and an average price target of $34.50.
Haemonetics Corp. (NYSE:HAE) opened at 37.68 on Tuesday. The firm’s market capitalization is $1.93 billion. Haemonetics Corp. has a one year low of $25.98 and a one year high of $38.06. The stock’s 50 day moving average price is $36.49 and its 200-day moving average price is $32.29.
Haemonetics Corp. (NYSE:HAE) last announced its quarterly earnings data on Monday, August 1st. The company reported $0.25 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.28 by $0.03. Haemonetics Corp. had a positive return on equity of 10.75% and a negative net margin of 7.25%. The firm had revenue of $210 million for the quarter, compared to analyst estimates of $205.41 million. During the same period in the previous year, the business posted $0.35 EPS. Haemonetics Corp.’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, equities research analysts anticipate that Haemonetics Corp. will post $1.44 earnings per share for the current fiscal year.
In other news, CEO Christopher Simon bought 60,000 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was bought at an average price of $35.00 per share, for a total transaction of $2,100,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ronald Merriman sold 4,337 shares of the business’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $35.14, for a total value of $152,402.18. Following the sale, the director now owns 22,088 shares of the company’s stock, valued at approximately $776,172.32. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in Haemonetics Corp. by 125.7% in the first quarter. BlackRock Inc. now owns 3,501 shares of the company’s stock worth $122,000 after buying an additional 1,950 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in Haemonetics Corp. during the second quarter worth $133,000. Invictus RG increased its stake in Haemonetics Corp. by 20.1% in the first quarter. Invictus RG now owns 4,074 shares of the company’s stock worth $143,000 after buying an additional 681 shares during the last quarter. PineBridge Investments L.P. increased its stake in Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock worth $187,000 after buying an additional 261 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in Haemonetics Corp. by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 7,081 shares of the company’s stock worth $205,000 after buying an additional 865 shares during the last quarter. Institutional investors own 98.64% of the company’s stock.
Haemonetics Corp. Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.